超声引导下指定层次穴位埋线治疗腹型单纯性肥胖的临床疗效研究

注册号:

Registration number:

ITMCTR2100004839

最近更新日期:

Date of Last Refreshed on:

2021-05-13

注册时间:

Date of Registration:

2021-05-13

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

超声引导下指定层次穴位埋线治疗腹型单纯性肥胖的临床疗效研究

Public title:

Clinical efficacy of ultrasound-guided Catgut Embedding at designated acupoints in the treatment of abdominal simple obesity

注册题目简写:

English Acronym:

研究课题的正式科学名称:

超声引导下指定层次穴位埋线治疗腹型单纯性肥胖的临床疗效研究

Scientific title:

Clinical efficacy of ultrasound-guided Catgut Embedding at designated acupoints in the treatment of abdominal simple obesity

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100046312 ; ChiMCTR2100004839

申请注册联系人:

李晓燕

研究负责人:

李晓燕

Applicant:

Li Xiaoyan

Study leader:

Li Xiaoyan

申请注册联系人电话:

Applicant telephone:

+86 13818782334

研究负责人电话:

Study leader's telephone:

+86 13818782334

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

lxy_0220@163.com

研究负责人电子邮件:

Study leader's E-mail:

lxy_0220@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市宝山区友谊路181号

研究负责人通讯地址:

上海市宝山区友谊路181号

Applicant address:

181 Youyi Road, Baoshan District, Shanghai

Study leader's address:

181 Youyi Road, Baoshan District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市宝山区中西医结合医院

Applicant's institution:

Shanghai Baoshan Hospital of Integrated Chinese and Western Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

202101

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

上海市宝山区中西医结合医院伦理委员会

Name of the ethic committee:

Ethics Committee of Shanghai Baoshan Hospital of Integrated Chinese and Western Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

1990/1/1 0:00:00

伦理委员会联系人:

丁任

Contact Name of the ethic committee:

Ding Ren

伦理委员会联系地址:

上海市宝山区友谊路181号

Contact Address of the ethic committee:

181 Youyi Road, Baoshan District, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市宝山区中西医结合医院

Primary sponsor:

Shanghai Baoshan Hospital of Integrated Chinese and Western Medicine

研究实施负责(组长)单位地址:

上海市宝山区友谊路181号

Primary sponsor's address:

181 Youyi Road, Baoshan District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市宝山区中西医结合医院

具体地址:

宝山区友谊路181号

Institution
hospital:

Shanghai Baoshan Hospital of Integrated Chinese and Western Medicine

Address:

181 Youyi Road, Baoshan District

经费或物资来源:

上海市宝山区科学技术委员会科技创新专项资金医学卫生项目

Source(s) of funding:

Shanghai Baoshan District Science and Technology Committee science and technology innovation fund medical and health project

研究疾病:

单纯性肥胖

研究疾病代码:

Target disease:

Simple obesity

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

观察超声引导下指定层次穴位埋线对腹型单纯性肥胖患者的临床疗效,明确最佳埋线层次,形成不同层次穴位埋线治疗腹型单纯性肥胖的临床操作方案。

Objectives of Study:

Objective To observe the clinical effect of ultrasound-guided acupoint catgut embedding at designated levels on patients with abdominal simple obesity, determine the best catgut embedding levels, and form the clinical operation scheme of different levels of acupoint catgut embedding in the treatment of abdominal simple obesity.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.符合腹型单纯性肥胖症诊断标准,属于中度肥胖,辨证分型为脾虚湿阻型; 2.年龄在18-60 岁之间,男女不限; 3.入组前3个月未接受其他治疗方式; 4.能接受穴位埋线治疗,签订知情同意书。

Inclusion criteria

1.According to the diagnostic criteria of abdominal simple obesity, it belongs to moderate obesity, and the syndrome differentiation is spleen deficiency and dampness stagnation; 2.Aged from 18 to 60 years, male and female; 3.There was no other treatment in the first 3 months; 4.Accept acupoint catgut embedding therapy and sign informed consent.

排除标准:

1.对异体蛋白过敏者; 2.合并内分泌疾病者; 3.合并各种肝病者; 4.继发性肥胖者; 5.精神疾病者; 6.合并器质性疾病者; 7.妊娠期、哺乳期女性; 8.由糖尿病及其他各种疾病导致皮肤和皮下组织吸收和修复功能障碍者; 9.埋线穴位皮肤局部有皮肤病、有炎症或溃疡、破损者。

Exclusion criteria:

1.Patients who were allergic to allogeneic protein; 2.Patients with endocrine diseases; 3.Patients with various liver diseases; 4.Patients with secondary obesity; 5.Patients with mental diseases; 6.Patients with organic diseases; 7.Women during pregnancy and lactation; 8.Patients with skin and subcutaneous tissue absorption and repair dysfunction caused by diabetes and other diseases; 9.Patients with skin diseases and inflammation in catgut embedding acupoints or ulcer or damage.

研究实施时间:

Study execute time:

From 2020-10-01

To      2023-06-30

征募观察对象时间:

Recruiting time:

From 2021-05-20

To      2022-09-30

干预措施:

Interventions:

组别:

健康组

样本量:

20

Group:

Health group

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

组别:

脂肪层组

样本量:

53

Group:

Fat layer group

Sample size:

干预措施:

超声引导性穴位埋线

干预措施代码:

Intervention:

Ultrasound guided acupoint catgut embedding

Intervention code:

组别:

肌肉层组

样本量:

53

Group:

Muscularis group

Sample size:

干预措施:

超声引导性穴位埋线

干预措施代码:

Intervention:

Ultrasound guided acupoint catgut embedding

Intervention code:

组别:

对照组

样本量:

53

Group:

Control group

Sample size:

干预措施:

常规穴位埋线

干预措施代码:

Intervention:

Routine catgut embedding at acupoints

Intervention code:

样本总量 Total sample size : 179

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市宝山区中西医结合医院

单位级别:

三级甲等

Institution/hospital:

Shanghai Baoshan Hospital of Integrated Chinese and Western Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

血清代谢标志物

指标类型:

附加指标

Outcome:

Serum metabolic markers

Type:

Additional indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

身高

指标类型:

主要指标

Outcome:

height

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

腰围身高比

指标类型:

次要指标

Outcome:

Waist - height ratio

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

脂质蓄积指数

指标类型:

次要指标

Outcome:

Lipid accumulation product

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

空腹胰岛素

指标类型:

次要指标

Outcome:

Fasting insulin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体重

指标类型:

主要指标

Outcome:

weight

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

低密度脂蛋白

指标类型:

次要指标

Outcome:

Low density lipoprotein

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总胆固醇

指标类型:

次要指标

Outcome:

total cholesterol

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

甘油三酯

指标类型:

次要指标

Outcome:

triglyceride

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

空腹血糖

指标类型:

次要指标

Outcome:

Fasting blood glucose

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

腹部脂肪厚度

指标类型:

次要指标

Outcome:

Abdominal fat thickness

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

稳态模型胰岛素抵抗指数

指标类型:

次要指标

Outcome:

HOMA-IR

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

糖化血红蛋白

指标类型:

次要指标

Outcome:

glycosylated hemoglobin

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

内脏脂肪指数

指标类型:

次要指标

Outcome:

visceral fat accumulation index

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

腰围

指标类型:

主要指标

Outcome:

waistline

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体质指数

指标类型:

主要指标

Outcome:

body mass index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

高密度脂蛋白

指标类型:

次要指标

Outcome:

High density lipoprotein

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 60
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

由课题负责人用Excel生成随机数字

Randomization Procedure (please state who generates the random number sequence and by what method):

The project leader generates random numbers with Excel

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

未说明 请阅读网页注册指南中关于“原始数据共享”的内容。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not stated

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统